Profil
Jaap Koopman is the founder of ProFibrix BV, which was founded in 2004, where he holds the title of Chief Scientific Officer, and Fibriant BV, which was founded in 2015, where he holds the title of Chief Executive Officer.
Prior to his founding positions, he worked at Pharming Group NV from 1998 to 2003, where he held the title of Scientific Director & Project Manager from 2003 to 2003.
Dr. Koopman received his doctorate degree from the University of Leiden in 1992.
Postes actifs de Jaap Koopman
| Sociétés | Poste | Début |
|---|---|---|
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Fondateur | 01/01/2004 |
Fibriant BV
 Fibriant BV Pharmaceuticals: OtherHealth Technology Fibriant BV is a Dutch biotechnology company that specializes in the recombinant manufacturing and characterization of specific variants of human Fibrinogen and active human Thrombin. The company is based in Leiden, the Netherlands. The company's science and technology are centered around Fibrinogen, a soluble blood protein that can be converted into an insoluble three-dimensional Fibrin network. Fibriant captures the unique features and functions of specific recombinant variants of Fibrinogen in new innovative products and in improvements of existing products based on plasma Fibrinogen. The company was founded in 2015 by Jaap Koopman, Jos Grimbergen, Miranda Weggeman, and Jaap Koopman has been the CEO since then. | Directeur Général | 01/01/2015 |
Anciens postes connus de Jaap Koopman
| Sociétés | Poste | Fin |
|---|---|---|
| PHARMING GROUP N.V. | Directeur Technique/Scientifique/R&D | 01/01/2003 |
Formation de Jaap Koopman
| University of Leiden | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PHARMING GROUP N.V. | Health Technology |
| Entreprise privées | 2 |
|---|---|
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Health Technology |
Fibriant BV
Fibriant BV Pharmaceuticals: OtherHealth Technology Fibriant BV is a Dutch biotechnology company that specializes in the recombinant manufacturing and characterization of specific variants of human Fibrinogen and active human Thrombin. The company is based in Leiden, the Netherlands. The company's science and technology are centered around Fibrinogen, a soluble blood protein that can be converted into an insoluble three-dimensional Fibrin network. Fibriant captures the unique features and functions of specific recombinant variants of Fibrinogen in new innovative products and in improvements of existing products based on plasma Fibrinogen. The company was founded in 2015 by Jaap Koopman, Jos Grimbergen, Miranda Weggeman, and Jaap Koopman has been the CEO since then. | Health Technology |